19:11 , May 31, 2019 |  BC Extra  |  Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
14:20 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. In a T...
19:23 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

CAR Ts targeting PD-L1, FnEDB for three solid tumor types

DISEASE CATEGORY: Cancer INDICATION: Cervical cancer; colorectal cancer; melanoma Cell culture and mouse studies suggest CAR T cells targeting PD-L1 or FnEDB could help treat cervical cancer, colorectal cancer and melanoma. In a mouse-cell based...
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
21:44 , Apr 2, 2019 |  BC Innovations  |  Distillery Techniques

Dual-targeting liposomes for cancer therapy delivery

TECHNIQUES CATEGORY: Drug delivery TECHNOLOGY: Nanoparticles Dual-targeting liposomes could be used to deliver cancer therapies. Generation of the liposomes involves two steps: screening human cancer cell lines against a 68-gene panel of common cancer targets...
13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer; gastrointestinal; inflammation

INDICATION: Breast cancer; colitis; asthma Mouse studies suggest inhibiting SPR could help treat colitis and asthma, and its biosynthetic product THB could help treat breast cancer. In a xenograft mouse model of breast cancer, THB...
18:56 , Dec 13, 2018 |  BC Innovations  |  Translation in Brief

3-D immune response

A Boston Children's Hospital team has developed a 3-D human tissue model that reproduces age-specific immune responses to vaccine antigens and could surmount the hurdles of developing vaccines for neonates and infants. Preclinical vaccine development...
16:11 , Dec 12, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model could help predict immune responses to vaccines. Generation and use of the model involves: placing a single layer of donor-derived human umbilical vein endothelial cells (HUVECs) over...
23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; cancer Patient sample, cell culture and mouse studies suggest inhibiting the METTL3-EIF3H interaction could help treat lung and other cancers. In tumor samples from patients with lung adenocarcinoma or seven other cancers,...
18:39 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Altheia lands $11M series A

Altheia Science s.r.l. (Milan, Italy) closed an $11 million series A round. The round could be expanded by another $6.7 million with the participation of institutional investors, the company said. Paolo Rizzardi, Altheia's chairman and...